Antibodies that bind interleukin-2 and uses thereof

Patent metadata

Field	Value
Publication number	US-12234285-B2
Application number	US-202017112664-A
Country	US
Kind code	B2
Filing date	Dec 4, 2020
Priority date	Sep 28, 2016
Publication date	Feb 25, 2025
Grant date	Feb 25, 2025

Abstract

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

First claim

What is claimed:

1. A method for treating a disease, condition or disorder associated with increased interleukin-2 (IL-2) or interleukin-2 receptor (IL-2 R) levels or activity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a human or humanized antibody that binds human interleukin-2 (IL-2) with an affinity K D of 1×10 −10 M or less and inhibits binding of IL-2 with an IL-2 receptor alpha (IL-2 Rα) subunit,
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ and through IL-2 Rβγ, and
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ to a greater extent than through IL-2 Rβγ,
wherein the disease, condition or disorder is cancer, and
wherein the antibody is administered in combination with IL-2 or an IL-2 variant.

2. The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, renal cell carcinoma, lymphoma, sarcoma, breast cancer, lung cancer, bladder cancer, colon cancer, gastric cancer, non small cell lung carcinoma (NSCLC), head and neck cancer, skin cancer, and squamous cell carcinoma (SCC).

3. The method of claim 2 , wherein the administration reduces tumor volume in the subject.

4. The method of claim 1 wherein the administration increases the ratio of CD8+T cells to CD4+T cells in the subject.

5. The method of claim 1 wherein the antibody is administered intravenously, intratumorally, intraarterially, intraperitoneally, intramuscularly, intradermally or subcutaneously.

6. The method of claim 1 , wherein the antibody is administered in combination with an additional therapeutic agent, optionally wherein the therapeutic agent is a checkpoint inhibitor, a chimeric antigen receptor T-cells/tumor-infiltrating lymphocytes (CART/TIL) agent, an antibody to a tumor antigen or a vaccine.

7. The method of claim 1 , wherein the antibody is administered once per week, once every 2 weeks, twice per month, once monthly, once every two months, or once every three months.

8. The method of claim 1 wherein the antibody comprises
i)
(a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs: 17, 20, 23, or 26;
(b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs: 18, 21, 24, or 27 that is from the same heavy chain variable region as (a); and
(c) a heavy chain CDR3 amino acid sequence set forth SEQ ID NOs: 19, 22, 25, or 28 that is from the same heavy chain variable region as (a); and,
ii)
(a) a light chain CDR1 amino acid sequence set forth in SEQ ID NOs: 29, 32, 35, or 38;
(b) a light chain CDR2 amino acid sequence set forth in SEQ ID NOs: 30, 33, 36, or 39 that is from the same light chain variable region as (a); and
(c) a light chain CDR3 amino acid sequence set forth in SEQ ID NOs: 31, 34, 37, or 40 that is from the same light chain variable region as (a).

9. The method of claim 8 , wherein the antibody comprises
an amino acid sequence at least 90% identical to a heavy chain variable region amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, or 7, and/or
an amino acid sequence at least 90% identical to a light chain variable region amino acid sequence set forth in any one of SEQ ID NOs: 9, 11, 13, or 15.

10. The method of claim 1 , further comprising a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof.

11. The method of claim 1 , in which one or more light chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

12. The method of claim 1 , wherein the antibody comprises
(a) heavy chain HCDR1-HCDR3 amino acid sequences set forth in SEQ ID NOs: 17-19; and
(b) light chain LCDR1-LCDR3 amino acid sequences set forth in SEQ ID NOs: 29-31.

13. The method of claim 1 , wherein the antibody comprises a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 9.

14. A method for suppressing IL-2 activity in a cell in vitro comprising the step of contacting the cell with an amount of an antibody that binds human interleukin-2 (IL-2) effective to suppress IL-2 activity in the cell, wherein the antibody is a human or humanized antibody that binds human interleukin-2 (IL-2) with an affinity K D of 1×10 −10 M or less and inhibits binding of IL-2 with an IL-2 receptor alpha (IL-2 Rα) subunit,
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ and through IL-2 Rβγ, and
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ to a greater extent than through IL-2 Rβγ.

Assignees

• Xoma Us Llc
• Musc Found For Res Dev

Inventors

• Roell Marina
• Rubinstein Mark
• Issafras Hassan
• Lao Llewelyn
• Li Ou
• Bedinger Daniel H
• Lind Kristin Camfield
• Holmes Agnes Choppin
• Takeuchi Toshihiko
• Schwimmer Lauren
• Giang Hoa
• Mirza Amer M
• Johnson Kirk W

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title